AllianceBernstein’s Marker Therapeutics MRKR Stock Holding History

AllianceBernstein’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,950	Closed	-$66K	–	3379
2021 Q1	$66K	Hold	2,950	–	–	﹤0.01%	3188
2020 Q4	$43K	Hold	2,950	–	–	﹤0.01%	3150
2020 Q3	$44K	Sell	2,950 -230	-7%	-$4.2K	﹤0.01%	3129
2020 Q2	$66K	Buy	3,180 +570	+22%	+$12.5K	﹤0.01%	3142
2020 Q1	$50K	Buy	2,610 +30	+1%	+$764	﹤0.01%	3054
2019 Q4	$74K	Hold	2,580	–	–	﹤0.01%	3070
2019 Q3	$132K	Buy	2,580 +720	+39%	+$42.5K	﹤0.01%	3032
2019 Q2	$147K	Buy	+1,860	New	+$110K	﹤0.01%	3023

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein's MRKR Position: Q2 2021 in Review

AllianceBernstein sold out of Marker Therapeutics (MRKR) in Q2 2021, closing a stake of 2,950 shares — an estimated $66K sold.

AllianceBernstein first reported a position in MRKR in Q2 2019 and held it in 8 quarters. The position peaked at $147K in Q2 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q2 2021.

AllianceBernstein reported no remaining Marker Therapeutics position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 2,950 Marker Therapeutics shares in Q2 2021, an estimated $66K.
AllianceBernstein first reported a position in Marker Therapeutics in Q2 2019 and held it in 8 quarters.
AllianceBernstein's Marker Therapeutics position peaked at $147K in Q2 2019.
74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.